Tirzepatide, a dual GIP/GLP-1 receptor agonist, powers both Mounjaro (diabetes) and Zepbound (weight management)
Additionally, 28% say they are more likely to try a GLP-1 medication for weight loss if it is promoted by a celebrity, such as Oprah, although 31% say they are less likely
Collected variables included demographics, diabetes duration, BMI, HbA1c, BMI z-scores, medication type and dose, and adverse effects
The modifications include amino acid substitutions and deletions that enhance the stability, potency and selectivity of the peptide for the three receptors (Finan et al., 2023, The New England Journal of Medicine)